Ask AI
ProCE Banner Series

Personalized Treatment in EGFR-Mutated NSCLC: Applying the Latest Clinical Evidence to Address Barriers and Improve Quality of Care

Specialty pharmacists enhance drug access and aid navigation of the evolving treatment regimens for patients with EGFR-mutated non-small-cell lung cancer. This module will present the ways that specialty pharmacists are uniquely positioned to prevent, mitigate, and manage adverse events emerging during treatment with EGFR-directed therapies while also optimizing adherence and reducing healthcare expenditures by maximizing treatment cost effectiveness.

  ACPE
Who Should Attend

The target audience for this activity is pharmacists—including specialty, managed care, and clinical pharmacists—who care for patients with advanced NSCLC, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice. 

Topics

Lung Cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC).

Target Audience
The target audience for this activity is pharmacists—including specialty, managed care, and clinical pharmacists—who care for patients with advanced NSCLC, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Conduct testing to enable the early detection and identification of actionable EGFR mutations, interpret the results, and determine implications for NSCLC treatment planning

  • Differentiate the mechanisms of action of tyrosine kinase inhibitors, bispecific antibodies, and other precision-targeted agents approved for EGFR-mutated NSCLC

  • Evaluate the latest clinical data to guide treatment selection for EGFR-mutated NSCLC, including patient-specific considerations, emphasizing strategies to improve outcomes and patient quality of life

  • Apply the latest evidence-based strategies to monitor, prevent, and manage AEs with EGFR-targeted therapies, including the use of prophylactic dermatologic regimens to reduce the incidence of skin and nail adverse reactions

Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-25-016-L01-P has been assigned to this live application-based activity (initial release date 11/6/2025). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles. 

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE, LLC policy. ProCE, LLC is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by ProCE, LLC In partnership with Clinical Care Options, LLC

ProCE, LLC

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Partners

Clinical Care Options, LLC

ProCE Banner

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191